CallidusCloud Announces 2017 Financial Analyst Day

DUBLIN, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ: CALD), a global leader in cloud-based sales, marketing, learning and customer experience solutions, today announced that it will host its financial analyst day on Tuesday, September 19, 2017 at 12:45pm PT (3:45pm ET) at CallidusCloud’s annual C3 Customer Conference.  CallidusCloud management participants will include Leslie Stretch, President and Chief Executive Officer, and Roxanne Oulman, Executive Vice President and Chief Financial Officer, as well as CallidusCloud partners and customers.

A webcast of the company’s presentation will be available on the "Investor Relations" section of the company's website at: http://www.calliduscloud.com/about-us/investor-relations/.

Blog: www.calliduscloud.com/salespulse  LinkedIn: www.linkedin.com/company/calliduscloud Facebook: www.facebook.com/callidussoftware   Twitter: @calliduscloud, @calliduscloudIRWeb: www.calliduscloud.com

About CallidusCloud Callidus Software Inc. (NASDAQ:CALD), doing business as CallidusCloud®, is the global leader in cloud-based sales, marketing, learning and customer experience solutions. CallidusCloud enables organizations to accelerate and maximize their Lead to Money process with a complete suite of solutions that identify the right leads, ensure proper territory and quota distribution, enable sales forces, automate configure price quote, and streamline sales compensation – driving bigger deals, faster. Approximately 5,700 leading organizations, across all industries, rely on CallidusCloud to optimize the Lead to Money process to close more deals for more money in record time.

For more information, please visit www.calliduscloud.com.

Investor Relations  Investor Relations Contact:Carolyn BassMarket Street Partners415-445-3232[email protected]

You May Also Be Interested In

• Hyundai Motor America names Steven Yandura VP of national sales
• Eglet Law Wins New Trial for Client in High-Profile General Motors Product Liability Case
• EU approves Merck's Keytruda plus Padcev for bladder cancer